Moxifloxacin Hydrochloride
💊 Brand Formulations & Prices
77 brands sorted by unit price
Maxiflox
Moxidal
Moxihil
Floromox
Maximox
Moxier
Moxif
Moxigen
Moxquin
Odycin
Respamox
Revalon
Topomox
Xiomox
Zydus
Floxalone
Moxana
Moxibest
Moxilocin
Visomox
MQ-4
Flomox
Iventi
Macflox
Moxiwell
Moxiwin
Moxkil
Moxiflox
Eramox
Verimox
Avaflox
Moxibac
Moxifix
Optimox
Floximox
Fomox
Glomox
Moxikem
Ocumox
Floxalone
Maxiflox
Moxif
Floromox
Floromox
Moxichem
Moxigen
Moxilocin
Moxivin
Optimox
MFC
Edrumox
Flomox
Moxilocin
Odycin
P-Moxlocin
Moxquin
Visomox
Cinagen
Eyemox
Iventi
Kilgen
Moxflo
Moxibac
Moxigen
Moxquin
Opthamox
Vigalon
Moxigram
Optimox
Maximox
Eramox
Iventi
Moxibac
Moxifix
Moxilocin
Moxquin
Optimox
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAvaflox tablet is indicated for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, uncomplicated & complicated skin and skin structure infections, complicated intra-abdominal infections and pelvic inflammatory disease.
Acute bacterial sinusitis
: 400 mg once daily 7-10 days.
Acute bacterial exacerbation of chronic bronchitis
: 400 mg once daily 5-10 days.
Community-acquired pneumonia
: 400 mg once daily 7-14 days.
Uncomplicated skin and skin structure infections
: 400 mg once daily 7 days.
Complicated skin and skin structure infections
: 400 mg once daily 7-21 days.
Complicated intra-abdominal infections
: 400 mg once daily 5-14 days.
Pelvic inflammatory disease
: 400 mg once daily 14 days.
It is contraindicated in patients with a history of hypersensitivity to Moxifloxacin or other quinolones.
Common side effects of Avaflox include nausea, vomiting, diarrhea, headache and dizziness.
Avaflox may cause an increased risk of tendinitis and tendon rupture. It should be discontinued if pain or inflammation in a tendon occurs. It should not be used in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients with receiving Class IA or Class III antiarrhythmic agents
Moxifloxacin is a 4th generation synthetic broad spectrum, fluoroquinolone class of antibacterial drug. It has activity against a wide range of gram-positive, gram-negative, anaerobic and atypical bacteria including Mycoplasma pneumoniae. It acts by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV which are necessary for bacterial DNA replication, transcription & repair.